Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Serotype 2 <i>?</i> <sub>1</sub> -Antitrypsin (AAT) Vector in AAT-Deficient Adults
Mark Brantly(University of Florida), Terence R. Flotte(University of Massachusetts Chan Medical School), Richard O. Snyder(Inserm), Nicholas Muzyczka(University of Florida), Sihong Song(American Association of Colleges of Pharmacy), Kenneth I. Berns(University of Alabama at Birmingham), L. Terry Spencer(University of Florida), Margaret Humphries(University of Massachusetts Chan Medical School), Barry J. Byrne(University of Florida), Wendy Garlington(University of Florida), Dawn Baker, Amy Poirier(University of Florida), Carolyn T. Spencer(University of Florida), Thomas J. Conlon(Adelson Foundation)
Cited by 0
Related Papers
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
|New England Journal of Medicine|2011|1.1k
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
|New England Journal of Medicine|2019|823
Molecular basis of alpha-1-antitrypsin deficiency
|The American Journal of Medicine|1988|501
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
|Circulation Research|2006|400